151 related articles for article (PubMed ID: 30762880)
1. Current challenges for CAR T-cell therapy of acute myeloid leukemia.
Sauer T; Rooney CM
Transfusion; 2019 Apr; 59(4):1171-1173. PubMed ID: 30762880
[TBL] [Abstract][Full Text] [Related]
2. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
3. Immune-Based Therapies in Acute Leukemia.
Witkowski MT; Lasry A; Carroll WL; Aifantis I
Trends Cancer; 2019 Oct; 5(10):604-618. PubMed ID: 31706508
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
[TBL] [Abstract][Full Text] [Related]
5. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.
John S; Chen H; Deng M; Gui X; Wu G; Chen W; Li Z; Zhang N; An Z; Zhang CC
Mol Ther; 2018 Oct; 26(10):2487-2495. PubMed ID: 30131301
[TBL] [Abstract][Full Text] [Related]
6. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
[TBL] [Abstract][Full Text] [Related]
7. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
9. Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
Lee JB; Chen B; Vasic D; Law AD; Zhang L
Blood Rev; 2019 May; 35():18-31. PubMed ID: 30826141
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.
Fiorenza S; Turtle CJ
BioDrugs; 2021 May; 35(3):281-302. PubMed ID: 33826079
[TBL] [Abstract][Full Text] [Related]
11. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
14. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
Front Immunol; 2018; 9():1971. PubMed ID: 30233577
[TBL] [Abstract][Full Text] [Related]
15. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
Restelli C; Ruella M; Paruzzo L; Tarella C; Pelicci PG; Colombo E
Blood Cancer Discov; 2024 Jul; 5(4):234-248. PubMed ID: 38904305
[TBL] [Abstract][Full Text] [Related]
17. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
18. Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.
Kenderian SS; June CH; Gill S
Methods Mol Biol; 2017; 1633():267-276. PubMed ID: 28735493
[TBL] [Abstract][Full Text] [Related]
19. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
20. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies.
Sterner RM; Kenderian SS
Curr Opin Hematol; 2020 Jan; 27(1):41-48. PubMed ID: 31764168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]